Overview

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
This study is designed to determine the effect of 2 gram/day of ethyl-EPA on motor (movement) signs and symptoms of Huntington disease.
Phase:
Phase 3
Details
Lead Sponsor:
Amarin Neuroscience Ltd
Collaborator:
Huntington Study Group
Treatments:
Eicosapentaenoic acid ethyl ester